Dr Richard Horniblow graduated with a first class master’s degree in Chemistry with Pharmacology from the University of Birmingham in 2011. He then went on to undertake a PhD from a BBSRC CASE studentship (sponsored by GlaxoSmithKline) in the fields of Medical Chemistry and Cancer Science under the supervision of Dr Chris Tselepis and Prof Zoe Pikramenou. Richard’s PhD research investigated the role of natural biopolymers and polyphenolic compounds as potential medicinal iron chelation agents. Upon successful completion in 2015, Richard continued to research his interests in the field of iron chelation and chemoprevention by undertaking a post-doctoral position within the Institute of Cancer and Genomic Sciences. With a highly multidisciplinary background, he has become interested in formulation development and drug delivery. Most recently in 2019, Richard became a lecturer in the School of Biomedical Science.
Throughout this research period, work has led to the development of potential therapeutic agents of which one bioactive has recently been assessed in a first-in-man clinical study. Richard has published a number of research articles in internationally recognised journals and has obtained grants from the BBSRC and Wellcome Trust to develop his translational research.
View Richards ResearchGate Profile